secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0001140361-24-044212
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma rebrands as Grace Therapeutics; new ticker GRCE effective Oct 28
------------------------------------------------------------------------------

- Company renamed Grace Therapeutics, Inc.; common stock begins trading as GRCE on Nasdaq at market open Oct 28, 2024.
- GTx-104 (nimodipine for aSAH) STRIVE-ON trial fully enrolled; data readout expected early 2025, NDA submission H1 2025.
- Virtual KOL event on GTx-104 scheduled for Nov 20, 2024 at 2pm ET.
- Company completed restructuring, rebuilt management, divested legacy assets, re-domiciled to Delaware.
- Addressable U.S. market for GTx-104 estimated at ~$300M; GTx-102 and GTx-101 development deprioritized.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036124044212/0001140361-24-044212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036124044212/ef20037632_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-044212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer